Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Druggable genome CRISPRi screen in hydrogels reveals regulators of cortactin-driven actin remodeling promoting glioblastoma invasion
Mufeng Hu, Anna Weldy, Isabella M. Lovalvo, Erin A. Akins, Saket Jain, Alexander Chang, Ankita Sati, Meeki Lad, Austin Lui, Akhil Rajidi, Ameya Kothekar, Erika A. Ding, Juan A. Oses Prieto, Pablo Estevez, Alma L. Burlingame, Sanjay Kumar, Manish K. Aghi
Mufeng Hu, Anna Weldy, Isabella M. Lovalvo, Erin A. Akins, Saket Jain, Alexander Chang, Ankita Sati, Meeki Lad, Austin Lui, Akhil Rajidi, Ameya Kothekar, Erika A. Ding, Juan A. Oses Prieto, Pablo Estevez, Alma L. Burlingame, Sanjay Kumar, Manish K. Aghi
View: Text | PDF
Research Article Cell biology Oncology

Druggable genome CRISPRi screen in hydrogels reveals regulators of cortactin-driven actin remodeling promoting glioblastoma invasion

  • Text
  • PDF
Abstract

To identify therapeutic targets limiting glioblastoma invasion, we applied druggable genome CRISPRi screens and multiomic analysis to patient-derived glioblastoma cells in micro-dissectible biomimetic 3D hydrogels that permitted separation and analysis of core versus invasive fractions. Of 2,550 genes screened, 12 encoded druggable targets whose suppression limited invasion, of which AURKB (encoding aurora kinase B) and ACP1 (encoding low molecular weight protein tyrosine phosphatase, LMW-PTP) were validated in neurosphere assays and in vivo. Proximity labeling identified cortactin as a link between LMW-PTP and aurora B, and we observed that cortactin underwent serine phosphorylation by aurora B and tyrosine dephosphorylation by LMW-PTP. Targeting ACP1 or AURKB via CRISPRi or inhibitors in culture and in vivo shifted the cortactin phosphorylation balance in glioblastoma, reducing levels of cortactin and the actin-related protein 2/3 (Arp2/3) complex that mediates cortactin-induced actin stabilization, thereby reducing actin-cortactin-Arp2/3 colocalization and subsequent actin polymerization. AURKB or ACP1 targeting shifted actin from cytoplasm to the nucleus, reducing mesenchymal gene expression. Biophysical analysis implicated AURKB in glioblastoma cell adhesion and stiffness needed for initial migration and ACP1 in mechanical stress resistance required for later migration. These findings revealed a targetable axis balancing kinase and phosphatase activities to regulate actin polymerization during glioblastoma invasion.

Authors

Mufeng Hu, Anna Weldy, Isabella M. Lovalvo, Erin A. Akins, Saket Jain, Alexander Chang, Ankita Sati, Meeki Lad, Austin Lui, Akhil Rajidi, Ameya Kothekar, Erika A. Ding, Juan A. Oses Prieto, Pablo Estevez, Alma L. Burlingame, Sanjay Kumar, Manish K. Aghi

×

Figure 3

Proximity labeling identifies cortactin as a binding partner for aurora B and LMW-PTP, and a key regulator of GBM invasion, whose expression increases in invasive GBM cells.

Options: View larger image (or click on image) Download as PowerPoint
Proximity labeling identifies cortactin as a binding partner for aurora ...
(A) Workflow for TurboID AURKB and ACP1. AURKB, ACP1, and control sequence encoding aa 1–29 of cytochrome P450 were fused to TurboID sequence, an engineered biotin ligase that converts biotin into biotin-AMP, covalently labeling proximal proteins. Biotinylated proteins were isolated using streptavidin magnetic beads and analyzed using mass spectrometry to identify binding partners. Created in BioRender. Lovalvo I. (2026) (https://BioRender.com/xudh77w). (B) Proteins bound to aurora B (AURKB) or LMW-PTP (ACP1) based on log2fold change of binding to aurora B versus cytochrome P450 (x axis) and the log2fold change of binding to LMW-PTP versus cytochrome P450 (y axis). Gray proteins did not significantly bind to either protein relative to cytochrome P450. Cyan proteins significantly bind to LMW-PTP. Pink proteins significantly bind to aurora B. Light purple proteins significantly bind to both targets versus control. The 8 proteins identified are part of the invasion-related KEGG pathways highlighted in C. (C) Genes for proteins significantly binding aurora B and LMW-PTP, stratified by gene expression in invasive versus core fractions of 3D hydrogels. (D) CellSCAPE analysis of cortactin (indicated by a purple diamond) interactions with known binding partners of aurora B (left) and LMW-PTP (right).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts